We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MG:NYSEMistras Group Inc Analysis

Data as of 2026-06-12 - not real-time

$18.82

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

MG is trading at $18.82, just below the calculated resistance of $19.24 and comfortably above the support of $16.40. The 20‑day SMA (17.75) sits marginally above the 50‑day SMA (17.69) and both are well above the 200‑day SMA (13.67), confirming a bullish price structure. Technical momentum is reinforced by an RSI of 59 and a bullish MACD histogram of 0.10, indicating continued upward pressure. Volatility is elevated at 44.5% over the past 30 days and beta of 1.32 points to higher systematic risk relative to the market. Nonetheless, the Fear & Greed Index reads "Extreme Greed" (88.95), suggesting strong investor appetite.
Fundamentals back the technical picture – Q1 revenue rose 4.6% to $731 M, gross margin expanded by 120 bps and EPS beat expectations at $0.07, driving a 75% earnings surprise. The forward PE of 15.1 is well below the industry average of 30.6, and the current PE of 26.9 signals a modest discount, giving an upside potential of roughly 12% to the consensus $21 target. The balance sheet is a concern: debt‑to‑equity stands at 107% and total debt ($251 M) exceeds cash on hand, raising leverage risk. The company pays no dividend, so income‑focused investors must rely on price appreciation. Overall, MG presents a growth‑oriented, yet risk‑weighted, investment case.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish technical setup (SMA crossover, MACD, RSI)
  • Q1 earnings beat and margin expansion
  • Price near support with upside to target

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustained revenue growth in aerospace & defense
  • Elevated leverage and debt levels
  • Forward PE indicating undervaluation

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Diversified global footprint exposing currency risk
  • High beta and volatility increasing systematic risk
  • No dividend requiring reliance on capital appreciation

Key Metrics & Analysis

Financial Health

Revenue Growth4.60%
Profit Margin3.06%
P/E Ratio26.9
ROE10.38%
ROA6.33%
Debt/Equity107.46
P/B Ratio2.6
Op. Cash Flow$30.1M
Free Cash Flow$2.9M
Industry P/E30.6

Technical Analysis

TrendBullish
RSI59.2
Support$16.40
Resistance$19.24
MA 20$17.75
MA 50$17.69
MA 200$13.67
MACDBullish
VolumeStable
Fear & Greed Index88.95

Valuation

Target Price$21.00
Upside/Downside11.58%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.32
Volatility44.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.